4D Molecular Therapeutics, Inc. (NASDAQ:FDMT Free Report) Investment analysts at Chardan Capital boosted their FY2023 earnings per share estimates for shares of 4D Molecular...

Share to Feed

Cantor Fitzgerald Weighs in on 4D Molecular Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:FDMT)Zolmax • 15 days ago

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT Free Report) Equities research analysts at Cantor Fitzgerald boosted their FY2023 EPS estimates for 4D Molecular Therapeutics in a note...

4DMT to Participate in Upcoming Investor ConferencesGlobe Newswire • 17 days ago

EMERYVILLE, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT, 4DMT, or the Company), a genetic medicines company with three novel, highly targeted next...

4D Molecular Therapeutics Continues Growth: Q3 Financials and Progress in Ophthalmology Trials Reinforce Buy RatingTipRanks Financial Blog • 22 days ago

Chardan Capital analyst Geulah Livshits has reiterated their bullish stance on FDMT stock, giving a Buy rating on November 2. Geulah Livshits has g...

4DMT Reports Third Quarter 2023 Financial Results and Operational HighlightsGlobe Newswire • 23 days ago

Rapidly advanced 4D-150 development for wet age-related macular degeneration (wet AMD): completed enrollment of PRISM Phase 2 Dose Expansion nearly two quarters earlier than expected and enrolled...

Buy Rating for 4D Molecular Therapeutics: An Analysis of Potential Growth and Future ProspectsTipRanks Financial Blog • 26 days ago

Leerink Partners analyst Mani Foroohar has maintained their bullish stance on FDMT stock, giving a Buy rating on November 2. Mani Foroohar's Buy ra...

4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis at 2023 NACFCGlobe Newswire • about 1 month ago

Aerosolized 4D-710 was generally well tolerated with no inflammation in any lung biopsy across Cohorts 1 and 2 (1E15 & 2E15 vg; n=7) with up to 17 months follow-upPromising, reproducible, CFTR...

4DMT Gains Alignment with FDA on Plan to Lift Clinical Hold on Phase 1/2 INGLAXA Clinical Trial for 4D-310 for Fabry Disease CardiomyopathyGlobe Newswire • about 1 month ago

Initiated single non-human primate (NHP) safety study evaluating intravenous 4D-310 combined with rituximab/sirolimus (R/S) immunosuppressive regimenAmended INGLAXA protocol to minimize risk of...

4D Molecular Therapeutics (NASDAQ:FDMT) Receives New Coverage from Analysts at Cantor FitzgeraldTicker Report • about 1 month ago

Cantor Fitzgerald started coverage on shares of 4D Molecular Therapeutics (NASDAQ:FDMT Free Report) in a research note issued to investors on Tuesday, Marketbeat reports. The firm issued an...

4D Molecular Therapeutics (FDMT, $10.61) Aroon Indicator entered a Downtrend on October 26, 2023.Tickeron - Stocks • about 1 month ago

For the last three days, A.I.dvisor has detected that FDMT's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Home
Symbol
FDMT
News

3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here.

Latest FDMT News

View

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Expected to Post FY2023 Earnings of ($2.70) Per Share

Zolmax • 15 days ago

Cantor Fitzgerald Weighs in on 4D Molecular Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:FDMT)

Zolmax • 15 days ago

4DMT to Participate in Upcoming Investor Conferences

Globe Newswire • 17 days ago

Join the conversation.This is where all the magic happens.